BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

This phase I trial studies the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer. The PI3K inhibitor BYL719 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving the PI3K inhibitor BYL719 together with letrozole may kill more tumor cells

NCT Number	NCT01791478
Lead Sponsor	Vanderbilt-Ingram Cancer Center Collaborators: National Cancer Institute (NCI)
Conditions	Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Enrollment	46 participants
Start Date	2013-04
Primary Completion	2014-12 (estimated)
Study Completion	2025-02-28 (estimated)
Updated on ClinicalTrials.gov	2024-07-23